Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 314326, 9 pages
Review Article

Targeted Therapies in Epithelial Ovarian Cancer

1Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
2Gynecologic Oncology Division, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA
3Gynecologic Oncology Unit, Department of Obstetrics & Gynecology, Hospital Sótero del Río, Santiago, Chile

Received 9 May 2009; Revised 13 October 2009; Accepted 22 October 2009

Academic Editor: Charles F. Levenback

Copyright © 2010 Nicanor I. Barrena Medel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Epithelial ovarian cancer remains a major women's health problem due to its high lethality. Despite great efforts to develop effective prevention and early detection strategies, most patients are still diagnosed at advanced stages of disease. This pattern of late presentation has resulted in significant challenges in terms of designing effective therapies to achieve long-term cure. One potential promising strategy is the application of targeted therapeutics that exploit a myriad of critical pathways involved in tumorigenesis and metastasis. This review examines three of the most provocative targeted therapies with current or future applicability in epithelial ovarian cancer.